Public market insider buying at Aptose Biosciences (APS)

Public market insider buying at Aptose Biosciences (T:APS)

Erich Platzer, a Director, acquired 270,000 Common Shares on a direct ownership basis at prices ranging from US$1.159 to US$1.198 on December 15th, 2021. This represents a $407,857 investment into the company's shares and an account share holdings change of greater than 100%.

William Glenn Rice, CEO and Director, acquired 13,183 Common Shares on a direct ownership basis at prices ranging from US$1.500 to US$1.530 on December 16th, 2021. This represents a $25,562 investment into the company's shares and an account share holdings change of 4.0%.

Aptose Biosciences is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Aptose Biosciences Inc. is a clinical-stage biotechnology company that is focused on discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company has two clinical-stage investigational products for hematologic malignancies: luxeptinib and APTO-253. The luxeptinib is a mutation agnostic Bruton's tyrosine kinase (BTK) kinase inhibitor, which is in a Phase I a/b trial in patients with refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies and is in a separate Phase I a/b trial in patients with refractory acute myeloid leukemia (AML). Its APTO-253 is the clinical stage agent that directly targets the Master Regulator of Cell Cycle Entry and Proliferative Metabolism (MYC) oncogene and suppresses its expression, which is in a Phase I a/b clinical trial for the treatment of patients with relapsed.